Asthma is the most important chronic disease of childhood.[@bib1] Prospective epidemiologic studies of respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) in early life have demonstrated subsequent rates of asthma and airway hyperreactivity 25% to 80% greater than in uninfected controls up to 11 years later.[@bib2], [@bib3], [@bib4], [@bib5] It is unclear whether most severe RSV LRTIs occur in predisposed patients with asthma or whether they are causal in subsequent asthma. We have used palivizumab (Synagis, MedImmune, Inc, Gaithersburg, Md; marketed outside the USA by Abbott, Abbott Park, Ill), a humanized mAb against the RSV fusion protein that prevents severe RSV LRTI, in a prospective matched double cohort multicenter study in premature infants to separate these effects.[@bib6] In a multivariate analysis, we demonstrated that by preventing severe RSV LRTI in infancy, later recurrent wheezing was reduced by 58% and physician-diagnosed recurrent wheezing by 65% compared to controls. However, a large study conducted in Wisconsin[@bib7] (the Childhood Origins of ASThma \[COAST\] study.) showed that in children with a strong family history of atopy, rhinovirus was the most important cause of development of children wheezing at 3[@bib7] and 6 years.[@bib8] Finally, a study from Australia showed that both rhinovirus and RSV interact with atopy in infancy to promote later asthma, suggesting that both of these are required in disease pathogenesis.[@bib9] Other studies from Canada[@bib10] showed that exposure to parainfluenza virus and RSV in the first year of life was associated with possible asthma at 2 years of age. A Spanish study showed that human metapneumovirus and RSV in infancy were associated with asthma at age 5 years,[@bib11] and the COAST Study showed that human coronavirus NL63 but not human metapneumovirus produced asthma at age 6 years.[@bib12]

Thus, the relationship between early RSV LRTI and allergic sensitization in the development of asthma at a later age is still unresolved. This controversy prompted us to examine the effect of the family history of atopy on the prevention of later recurrent wheezing in premature infants who had received palivizumab in the first year of life compared to controls.

Methods {#sec2}
=======

Patient enrollment {#sec2.1}
------------------

This prospective multicenter, matched, double cohort study was conducted in 27 centers in Spain, Germany, The Netherlands, Canada, Poland, and Sweden as described earlier.[@bib6] Briefly, children ≤36 months of age who had received palivizumab in a previous respiratory season and were not hospitalized for RSV were matched on the basis of gestational age (\<28 weeks, 28-32 weeks, 29-35 weeks) and age (±3 months) to control children who had never received palivizumab. There were 2 control groups: approximately one third had documented RSV hospitalization in the first year before enrollment (n = 76), and the second group (n = 154) was not hospitalized. All study participants were born prematurely (\<36 weeks gestational age) without chronic lung disease and had never received vaccines to prevent RSV. Other exclusion criteria were mechanical ventilation at enrollment, a life expectancy of \<6 months, or a known immunodeficiency.

Written informed consent was obtained from each subject\'s parent or legal guardian before performance of any study-related procedures. The study was conducted according to International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Good Clinical Practice Guidelines. At enrollment, a medical and sociodemographic history was taken, a physical examination was performed, and serum was obtained for RSV neutralizing antibody and IgE level.[@bib6]

Patient follow-up {#sec2.2}
-----------------

Monthly contact with the parents/caregivers was scheduled for 24 months after enrollment. Visits to the study site were conducted at 6-month intervals; all other monthly contacts were conducted by telephone. The patient\'s illnesses, medications, hospitalizations, and other medical events in the past month were recorded at each of the monthly follow-up contacts. At 6-month intervals, physician records were also reviewed for all intercurrent doctor visits, emergency visits, and hospitalizations for respiratory symptoms.

Respiratory assessment {#sec2.3}
----------------------

An episode of wheezing was defined as 1 or more consecutive days of wheezing preceded and followed by a nonwheezing healthy period of at least 1 week. Physician-diagnosed recurrent wheezing was defined as 3 or more episodes of wheezing in the last 12 months verified by a physician at a physician\'s visit, emergency department visit, or hospitalization.

Statistical methods {#sec2.4}
-------------------

This report includes all data collected through 24 months of follow-up. Three study groups were defined in the protocol (infants who received palivizumab prophylaxis, controls not prophylaxed with palivizumab with a history of RSV hospitalization, and unprophylaxed controls without RSV hospitalization). Analyses compared the prophylaxed group with the combined untreated groups and the nonhospitalized untreated group*. Post hoc* subgroups of infants were determined on the basis of whether the following were present at baseline: family history of asthma and family history of atopy (asthma, atopic dermatitis, or allergic rhinitis) or food allergies. Family was defined as anyone in the immediate family. Analyses were performed within these subgroups. A sample size of 200 infants per group would provide approximately 80% power for a 2-sided, .05-level test to detect as statistically significant a difference in physician-diagnosed recurrent wheezing rates when the true rates were 3% for the prophylaxed group and 10% for the untreated controls. This study was not powered to test for differences within the subgroups previously specified.

Demographics and baseline characteristics were analyzed for quantitative variables by using 1-way ANOVA and for categorical variables by using the Fisher exact test. Comparisons between the treated and untreated groups in incidence of physician-diagnosed recurrent wheezing were performed by using the Fisher exact test; the relative risk (RR) and 95% CI for the RR were calculated. The potential influence of baseline characteristics was explored with multiple logistic regression with covariates for RSV hospitalization history, sex, age at enrollment, gestational age at birth, birth weight, multiple birth status, baseline RSV-neutralizing antibody titers (log~2~ RSV antibody level), day care attendance, numbers of adults and siblings in the home, number of siblings in day care, presence of a wood-burning stove in the home, and family history of asthma, atopic dermatitis, allergic rhinitis, or food allergies. Time to third physician-diagnosed wheezing episode was analyzed with multivariable Cox proportional hazards models including the covariates listed. For each logistic regression and Cox proportional hazards analysis, a forward stepwise selection method was used to determine factors significant at the .15 level; these factors were included in the final model. Only factors significant at the .05 level in the final model were displayed. Comparisons between the treated and untreated groups in time to third physician-diagnosed wheezing episode were performed by using the log-rank test, and Kaplan-Meier estimates were computed and displayed graphically.

Results {#sec3}
=======

There were 191 children in the palivizumab-treated group and 230 in the untreated group, among whom 154 were not hospitalized with RSV and 76 were hospitalized with RSV. Of the 27 centers that enrolled subjects, 13 had subjects discontinue on or before day 730 (2-year cutoff). Sixteen (8.4%) in the palivizumab-treated group versus 21 (9.1%) in the 230 children not receiving palivizumab were discontinued before day 730. This difference was not statistically significant (*P* = .864). Demographics and baseline characteristics of the groups stratified by absence or presence of family history of atopy or food allergies are presented in [Table I](#tbl1){ref-type="table"}, [Table II](#tbl2){ref-type="table"} , respectively. There were 201 children with no family history of atopy or food allergies and 220 children with a family history of atopy or food allergies who were enrolled in the study. In the subjects with no family history of atopy or food allergies, both untreated groups had significantly more children who were from multiple births, and accordingly there were more siblings than in the palivizumab-treated group ([Table I](#tbl1){ref-type="table"}). In those with family history of atopy or food allergies, there were more children in day care in the untreated groups compared to the treated group. In both of these subgroups, the untreated infants had greater mean gestational age and birth weight than the palivizumab-treated infants ([Table I](#tbl1){ref-type="table"}, [Table II](#tbl2){ref-type="table"}). This was expected because guidelines for palivizumab use favor treatment for smaller, more premature infants. The combined untreated group also had a statistically significantly lower proportion of infants with baseline RSV antibody less than 2log~2~ compared to the treated group, within the subgroup of infants with no family history of atopy or food allergies. Other demographic factors were comparable between the treated and untreated groups.Table IDemographics and baseline characteristics---subjects with no family history of atopy (asthma, atopic dermatitis, or allergic rhinitis) or food allergiesPalivizumab treatedPalivizumab untreatedPalivizumab untreated non-RSV hospitalizedVariable(n = 101)(n = 100)(n = 75[§](#tblfn4){ref-type="table-fn"})Mean birth weight (kg) ± SD (range)1.36 ± 0.45 (0.7-2.5)1.60 ± 0.47[‡](#tblfn3){ref-type="table-fn"} (0.6-2.7)1.55 ± 0.45[†](#tblfn2){ref-type="table-fn"} (0.6-2.7)Mean gestational age (wk) ± SD (range)29.9 ± 2.36 (25-34)31.5 ± 2.58[‡](#tblfn3){ref-type="table-fn"} (24-35)31.3 ± 2.63[‡](#tblfn3){ref-type="table-fn"} (24-35)Female sex (%)43.649.052.0White race (%)97.095.096.0Multiple birth (%)17.834.0†30.7[∗](#tblfn1){ref-type="table-fn"}Mean enrollment age (mo) ± SD (range)19.4 ± 7.46 (5-40)20.5 ± 9.45 (1-37)20.1 ± 9.63 (1-37)Mean enrollment weight (kg) ± SD (range)10.26 ± 1.95 (4.9-16.2)10.23 ± 2.78 (3.1-16.5)10.00 ± 2.70 (3.1-16.5)Breast-fed (%)55.451.052.0Mean no. of siblings ± SD (range)0.7 ± 0.78 (0-3)1.2 ± 1.04[‡](#tblfn3){ref-type="table-fn"} (0-4)1.1 ± 1.01[∗](#tblfn1){ref-type="table-fn"} (0-4)Siblings in day care (%)28.737.038.7Subject in day care (%)24.817.018.7Smokers in home (%)49.557.060.0Caregiver smokes (%)27.728.033.3Pets in home (%)37.627.030.7Wood-burning stove (%)16.815.020.0RSV antibody (% \<2log~2~)47.030.3[∗](#tblfn1){ref-type="table-fn"}39.2IgE antibody (% \<5 IU/mL)59.649.548.6[^2][^3][^4][^5]Table IIDemographics and baseline characteristics---subjects with family history of atopy (asthma, allergic dermatitis, or allergic rhinitis) or food allergiesPalivizumab treatedPalivizumab untreatedPalivizumab untreated non-RSV hospitalizedVariable(n = 90)(n = 130)(n = 79[§](#tblfn8){ref-type="table-fn"})Mean birth weight (kg) ± SD (range)1.36 ± 0.44 (0.6-3.2)1.65 ± 0.54[‡](#tblfn7){ref-type="table-fn"} (0.6-3.8)1.58 ± 0.45[†](#tblfn6){ref-type="table-fn"} (0.6-2.7)Mean gestational age (wk) ± SD (range)29.9 ± 2.08 (25-35)31.3 ± 2.44[‡](#tblfn7){ref-type="table-fn"} (25-35)31.0 ± 2.26[†](#tblfn6){ref-type="table-fn"} (27-35)Female sex (%)53.342.340.5White race (%)93.395.496.2Multiple birth (%)33.339.238.0Mean enrollment age (mo) ± SD (range)17.9 ± 8.11 (4-36)19.5 ± 9.76 (1-38)18.9 ± 10.92 (1-38)Mean enrollment weight (kg) ± SD (range)10.19 ± 2.59 (3.8-19.3)10.12 ± 2.81 (2.6-16.6)9.77 ± 2.94 (3.1-16.6)Breast-fed (%)71.168.568.4Mean number of siblings ± SD (range)1.0 ± 1.01 (0-5)1.3 ± 1.02[∗](#tblfn5){ref-type="table-fn"} (0-5)1.1 ± 0.93 (0-4)Siblings in day care (%)40.052.348.1Subject in day care (%)20.033.1[∗](#tblfn5){ref-type="table-fn"}36.7[∗](#tblfn5){ref-type="table-fn"}Smokers in home (%)43.336.939.2Caregiver smokes (%)27.821.522.8Pets in home (%)33.333.831.6Wood-burning stove (%)13.313.815.2Family history of asthma (%)50.045.449.4Family history of atopic dermatitis %)16.719.216.5Family history of allergic rhinitis (%)56.754.654.4Family history of food allergies (%)14.416.217.7Family history of any atopy (%)94.490.888.6Family history of any atopy or food allergies (%)100100100RSV antibody (% \<2log2)38.429.438.5IgE antibody (% \<5 IU/ML)49.453.357.9[^6][^7][^8][^9]

Significantly smaller proportions of palivizumab-treated children had physician-diagnosed recurrent wheezing during the first 24 months of follow-up compared to the combined untreated groups in the subgroups of children with (1) no family history of asthma (*P* = .039) and (2) no family history of atopy or food allergies (*P* = .012). Similar differences between the palivizumab-treated group and the nonhospitalized untreated group were also seen; however, the difference within the subgroup with no family history of asthma was not statistically significant (*P* = .083; [Fig 1](#fig1){ref-type="fig"} ). The relative incidence rate reductions were not significant for the subgroups of infants with a family history of allergy or atopy/food allergy ([Fig 1](#fig1){ref-type="fig"}).Fig 1Effect of palivizumab on physician-diagnosed recurrent wheezing in infants with or without a family history of asthma or atopy or food allergies. Results are expressed as frequencies of outcome in univariate analyses. The results are graphically represented as point estimates of the RRs and 95% CIs.

The potential influence of baseline characteristics on the incidence of respiratory outcomes was explored with multiple logistic regression ([Table III](#tbl3){ref-type="table"} ). Palivizumab treatment was associated with significant reductions in the risk of physician-diagnosed recurrent wheezing in infants without familial atopy/allergy histories. The reduction in the odds of an event was 68% in those with no family history of asthma and 80% in those with no history of atopy or food allergies. In contrast, in those subgroups with a family history of atopy or food allergies, palivizumab treatment did not have a significant effect on the occurrence of physician-diagnosed recurrent wheezing. Other significant factors in those with no family history of asthma or atopy/food allergies were birth weight and/or gestational age (with greater values reducing the risk of the event). In contrast, in children with a family history of asthma, being a member of a multiple birth and having more siblings in day care significantly increased the risk of physician-diagnosed recurrent wheezing, whereas having more siblings in the home decreased the risk.Table IIIFactors associated with occurrence of physician-diagnosed recurrent wheezing by multiple logistic regression for subgroups based on family historyOdds ratio (95% CI)No historyHistoryVariablevs combined untreated groupsvs untreated non-RSV hospitalized groupvs combined untreated groupsvs untreated non-RSV hospitalized groupAsthma Palivizumab treatment0.32 (0.14-0.75)[†](#tblfn10){ref-type="table-fn"}0.32 (0.13-0.80)[∗](#tblfn9){ref-type="table-fn"}NANA Member of multiple birthNANA6.63 (1.64-26.74)[†](#tblfn10){ref-type="table-fn"}NA Siblings in householdNANA0.30 (0.09-0.98)[∗](#tblfn9){ref-type="table-fn"}NA Siblings in day careNANA5.40 (1.47-19.86)[∗](#tblfn9){ref-type="table-fn"}2.02 (1.07-3.82)[∗](#tblfn9){ref-type="table-fn"} Birth weight0.35 (0.15-0.81)[∗](#tblfn9){ref-type="table-fn"}NANANA Gestational age (per 1-wk increase)NA0.78 (0.66-0.93)†NANAAtopy (asthma, atopic dermatitis, or allergic rhinitis) or food allergies Palivizumab treatment0.20 (0.07-0.59)[†](#tblfn10){ref-type="table-fn"}0.18 (0.06-0.55)[†](#tblfn10){ref-type="table-fn"}NANA Family history of asthmaNANANA3.10 (1.12-8.62)[∗](#tblfn9){ref-type="table-fn"} Gestational age (per 1-wk increase)0.82 (0.68-0.98)[∗](#tblfn9){ref-type="table-fn"}0.79 (0.65-0.96)[∗](#tblfn9){ref-type="table-fn"}NA0.80 (0.64-1.00)[∗](#tblfn9){ref-type="table-fn"}[^10][^11][^12]

When we examined the time to the third episode of physician-diagnosed wheezing by using Kaplan-Meier methodology ([Fig 2](#fig2){ref-type="fig"} ), the palivizumab-treated group demonstrated significantly longer times to the third episode in subgroups of infants with no family history of asthma or atopy/food allergies. In contrast, in the subgroups of infants with family histories of asthma or atopy/food allergies, the differences in time to third episode between the treated and untreated groups were not statistically significant. The potential influence of baseline characteristics on time to the third episode of physician-diagnosed wheezing was explored by using a multivariate Cox proportional hazards regression model. Palivizumab treatment remained associated with a significantly longer time to the third episode in both of the subgroups of infants with no family history of asthma and those with no family atopy/food allergy histories ([Table IV](#tbl4){ref-type="table"} ). Greater gestational age was also associated with a longer time to the third episode in these subgroups. In contrast, palivizumab did not appear to have a significant effect on those with family histories of asthma or atopy/food allergies. Interestingly, in the subgroup of infants with a family history of atopy or food allergy, a family history of asthma was the most significant risk factor for the time to the third episode of physician-diagnosed wheezing.Fig 2Kaplan-Meier plots (A-D) showing the time to the third episode of physician-diagnosed wheezing in palivizumab-treated group *(solid gray line)* versus combined untreated groups *(solid black line)* and palivizumab-treated group versus nonhospitalized untreated group *(dashed line)*.Table IVFactors associated with time to onset of physician-diagnosed recurrent wheezing by multivariable Cox proportional hazards regression for subgroups based on family historyHazard Ratio (95% CI)No historyHistoryVariablevs combined untreated groupsvs untreated non-RSV hospitalized groupvs combined untreated groupsvs untreated non-RSV hospitalized groupAsthma Palivizumab treatment0.33 (1.51-0.74)[†](#tblfn12){ref-type="table-fn"}0.34 (0.15-0.79)[∗](#tblfn11){ref-type="table-fn"}NANA Member of multiple birthNANA11.09 (2.14,57.45)[†](#tblfn12){ref-type="table-fn"}NA Siblings in householdNANA0.27 (0.09-0.81)[∗](#tblfn11){ref-type="table-fn"}NA Siblings in day careNANA6.36 (1.76-22.99)[†](#tblfn12){ref-type="table-fn"}1.84 (1.10-3.09)[∗](#tblfn11){ref-type="table-fn"} Gestational age (per 1-wk increase)0.84 (0.73-0.96)[†](#tblfn12){ref-type="table-fn"}0.79 (0.67-0.92)[†](#tblfn12){ref-type="table-fn"}NANAAtopy (asthma, atopic dermatitis, or allergic rhinitis) or food allergies Palivizumab treatment0.21 (0.08-0.59)[†](#tblfn12){ref-type="table-fn"}0.20 (0.07-0.56)†NANA Family history of asthmaNANA3.77 (1.60-8.92)[†](#tblfn12){ref-type="table-fn"}2.94 (1.14-7.61)[∗](#tblfn11){ref-type="table-fn"} Gestational age (per 1-wk increase)0.82 (0.70-0.96)[∗](#tblfn11){ref-type="table-fn"}0.80 (0.67-0.95)[∗](#tblfn11){ref-type="table-fn"}NA0.81 (0.66-0.98)[∗](#tblfn11){ref-type="table-fn"}[^13][^14][^15]

Discussion {#sec4}
==========

The results of the COAST Study[@bib7], [@bib8], [@bib12] and the subsequent study from Australia[@bib9] appear to be in contrast to our initial findings that the administration of palivizumab in infancy protects premature subjects against subsequent recurrent wheezing in the first 3 to 4 years of life.[@bib6] This prompted us to examine the potential for a differential effect of RSV prevention in those with and without an atopic diathesis. Our finding of a significant protection in children with no family history of asthma or atopy does suggest that the differences may be explained by an atopic diathesis. Thus, whereas our study was conducted in preterm children, and whereas we recruited almost equivalent numbers of children with an atopic background and a nonatopic background, the COAST Study consisted almost entirely of infants with an atopic background.[@bib7] Because we did not examine the effects of rhinovirus infection in early infancy in children in the atopic group, we could not comment on the relationship between early rhinovirus infection and later subsequent asthma. However, the apparent lack of an effect of prevention of RSV in atopic subjects fits in well with the apparent lack of an independent effect of early life RSV seen in the COAST Study.[@bib7] The relatively low number of children in our study with a family history of asthma may in part explain the nonsignificant reduction in that group. In the group of children with an atopic family history, however, there was almost the same number of children as with no atopic history. The consistency of our findings in all the subgroups on the basis of the absence of family atopy/allergy history and the increasing protection (at least for the point estimates) as successive atopic backgrounds are removed (from a family history of asthma to family history of atopy or food allergies), despite a lower number of children with no family history of atopy or food allergies, suggest that our observation is real.

The subjects in this trial were recruited at the mean age of 19 months (range, 1-40 months). It is possible that some of these children already had recurrent wheezing (3 or more episodes of physician-diagnosed recurrent wheezing) before that age. When we examined the subgroup of children with no family history of atopy or food allergy with multiple logistic regression, palivizumab treatment reduced the risk of physician-diagnosed recurrent wheezing by 80%; this was in contrast with palivizumab not having a significant effect in those with such a history. Children with recurrent wheezing in this group may have had recurrent wheezing for several reasons. A minority would have asthma starting early in life, and some would be those with recurrent wheezing after RSV, occurring before enrollment. These would be few, because our definition was 3 or more episodes of recurrent wheezing (in this case, before enrollment). Because subjects were between 2 and 5 years of age at the completion of the study, this may be too early for hereditary allergic factors to exert their effect on wheezing. However, allergic factors may have exerted an effect, because the influence of palivizumab was less apparent in these subjects. The children within the group with the most protection thus probably had no atopic diathesis and would probably not go on to develop asthma in later life. It is precisely within this group that the maximum protection was seen.

Because none of the patients in the palivizumab group and 33% of the control group were hospitalized with RSV, it is possible that the results reflect the more severe previous RSV disease in the control group.[@bib13] Hence, we compared the outcomes in the treated and control groups that were not hospitalized for RSV. There were still significant differences between the palivizumab-treated and the nonhospitalized untreated group in those subgroups with no family histories of atopy or food allergies. The logistic regression analysis once again showed that the major factor associated with a reduction in physician-diagnosed recurrent wheezing was treatment with palivizumab in those without an atopic diathesis.

A family history of atopy or asthma may be a risk factor for severe LRTI in early life[@bib14], [@bib15] or RSV hospitalization.[@bib16], [@bib17] In patients with a family history of asthma, the effect of palivizumab appeared to be marginal, suggesting that the atopic or asthmatic background is a severe enough predisposing factor for the development of later occurring wheezing, and perhaps RSV infection does not increase that risk very much. This thesis is supported in part by our observation in the Cox regression model clearly showing that in those with an atopic diathesis or food allergies, the family history of asthma is still the strongest predictor of recurrent wheezing later, and prevention by palivizumab of RSV does not appear to have any significant effect in this population. This study shows a protective effect of 65% in the overall population and 80% in those with no background of atopy or food allergies, and the consistency of the effect appears to be a strong indicator that RSV may lead to recurrent wheezing in this population. Whether this effect persists into later childhood or into adult life is a question that remains to be answered.

Studies from Australia seem to suggest that early-life respiratory infections with either RSV or rhinovirus in conjunction with atopic sensitization may contribute to the risk for subsequent development of persistent asthma.[@bib9] At the same time, studies from Tucson[@bib18] predict that children with persistent wheezing at the age of 6 years in conjunction with a family history of asthma predict the onset of later asthma in adulthood.[@bib19] Our study clearly cannot answer questions about the genesis of later childhood asthma or adult-onset asthma, but the observation does lend itself to the intriguing possibility that perhaps preventing RSV infection early in life prevents sensitization and potentially the development of later asthma. This hypothesis was suggested by data from a mouse model of infection and supported by a study of RSV prophylaxis in human beings. In the mouse model of RSV infection, it has been shown that respiratory infections of young mice sensitize the mice to aeroallergens to which they were exposed during infection.[@bib20] However, a more recent study suggests that remodeling after RSV in the mouse model occurs without sensitization.[@bib21] In a previous study using RSV immunoglobulin,[@bib22] it was suggested that the combined immunosuppressive effect of high doses of monthly prophylactic immunoglobulin and the anti-RSV activity of the RSV immunoglobulin given to children with chronic lung disease of prematurity abrogated the development of abnormal lung function at 7 to 9 years of age. Future studies (randomized control trials) of RSV infection using mAbs in children with and without an atopic background are being planned to address the role of RSV in the development of subsequent asthma.

In premature infants, the prevention of RSV by using palivizumab in children without an atopic background appears to decrease by 80% the relative risk of recurrent wheezing from 2 to 5 years of age, an effect that is not seen in those with an atopic background.

Clinical implicationsRSV prophylaxis with palivizumab significantly reduced the relative risk of subsequent recurrent wheezing in nonatopic premature infants.
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